Loading…
ONDANSETRON is a brand name for Ondansetron, supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ........................................................................... 3 CONTRAINDICATIONS ................................................................................................. 4 WARNINGS AND PRECAUTIONS ............................................................................... 4…
Verbatim from this product's HC label. Tap a section to expand.
Ondansetron Injection BP (ondansetron hydrochloride) is contraindicated in patients with a history of hypersensitivity to the drug or any components of its formulation. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING.
The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron. WARNINGS AND PRECAUTIONS Immune Cross-reactive hypersensitivity has been reported between different 5-HT3 antagonists.
Patients who have experienced hypersensitivity reactions to one 5-HT3 antagonist have experienced more severe reactions upon being challenged with another drug of the same class. The use of a different 5-HT3 receptor antagonist is not recommended as a replacement in cases in which a patient has experienced even a mild hypersensitivity type reaction to another 5-HT3 antagonist.
Cardiovascular QTc Interval Prolongation:
Ondansetron prolongs the QT interval (see ACTION AND CLINICAL PHARMACOLOGY, Electrocardiography). The magnitude of QTc prolongation will depend on the dose and the infusion rate. In addition, post-marketing cases of torsade de pointes have been reported in patients using ondansetron.
Torsade de pointes is a polymorphic ventricular tachyarrhythmia. Generally, the risk of torsade de pointes increases with the magnitude of QTc prolongation produced by the drug. Torsade de pointes may be asymptomatic or experienced by the patient as dizziness, palpitations, syncope, or seizures.
If sustained, torsade de pointes can progress to ventricular fibrillation and sudden cardiac death. Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to either QT prolongation or electrolyte abnormalities (see DRUG INTERACTIONS).
Hypokalaemia, hypocalcaemia and hypomagnesemia should be corrected prior to ondansetron administration. , eating disorders, extreme diets); diabetes mellitus; autonomic neuropathy. Ondansetron Injection BP (ondansetron hydrochloride) is not effective in preventing motion- induced nausea and vomiting.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Ondansetron in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
General Neurologic Serotonin syndrome/Neuroleptic Malignant Syndrome:
Cases of life-threatening serotonin syndrome or neuroleptic malignant syndrome-like events have been reported with 5-HT3 receptor antagonist antiemetics, including ondansetron hydrochloride, when given in combination with other serotonergic and/or neuroleptic drugs.
g. nausea, vomiting, diarrhoea). As these syndromes may result in potentially life-threatening conditions, treatment should be discontinued if such events occur and supportive symptomatic treatment should be initiated. If concomitant treatment of Ondansetron Injection BP with a drug affecting the serotonergic neurotransmitter system is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see DRUG INTERACTIONS).
Hepatic/Biliary/Pancreatic There is no experience in patients who are clinically jaundiced. The clearance of an 8 mg intravenous dose of ondansetron hydrochloride was significantly reduced and the serum half-life significantly prolonged in subjects with severe impairment of hepatic function.
In patients with moderate or severe impairment of hepatic function, reductions in dosage are therefore recommended and a total daily dose of 8 mg should not be exceeded. This may be given as a single intravenous or oral dose. Ondansetron does not itself appear to induce or inhibit the cytochrome P450 drug-metabolizing enzyme system of the liver.
Because ondansetron is metabolised by hepatic cytochrome P450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. On the basis of available data, no dosage adjustment is recommended for patients on these drugs.
Gastrointestinal As ondansetron is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration. Page 6 of 31 Reproduction Pregnancy status should be verified for females of reproductive potential prior to starting the treatment with Ondansetron Injection BP.
Females of reproductive potential should be advised that it is possible that Ondansetron Injection BP can cause harm to the developing foetus. Sexually active females of reproductive potential are recommended to use effective contraception (methods that result in less than 1% pregnancy rates) when using Ondansetron Injection BP and for two days after stopping treatment with Ondansetron Injection BP.
Special Populations Pregnant Women:
The use of ondansetron in pregnancy is not […]
+1 more